COST-EFFECTIVENESS OF WEEKLY GASTRO-RESISTANT RISEDRONATE 35 MG, COMPARED WITH WEEKLY ALENDRONATE TABLETS, IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SPAIN

被引：0

作者：

Casado, E. ^{[1
]}

Rosas, J. C. ^{[2
]}

Aristegui, I. ^{[3
]}

Rubio-Terres, C. ^{[4
]}

Rubio-Rodriguez, D. ^{[4
]}

机构：

[1] Univ Hosp Parc Tauli, Dept Rheumatol, Barcelona, Spain

[2] Hosp Marina Baixa, Dept Rheumatol, Alicante, Spain

[3] Theramex, London, England

[4] Hlth Value, Madrid, Spain

来源：

AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2023年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

P614

引用

页码：S333 / S333

页数：1

共 50 条

[1] Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
Casado, Enrique
Rosas, Jose
Rubio-Terres, Carlos
Rubio-Rodriguez, Dario
Boolell, Mitra
Aristegui, Ignacio
[J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (11)
[2] COST-EFFECTIVENESS OF ACTONEL® 35 MG (RISEDRONATE) GASTRO-RESISTANT TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE
Hiligsmann, M.
Reginster, J.
[J]. VALUE IN HEALTH, 2018, 21 : S298 - S298
[3] Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
M. Hiligsmann
J.-Y. Reginster
[J]. Osteoporosis International, 2019, 30 : 649 - 658
[4] COST-EFFECTIVENESS OF GASTRO-RESISTANT RISEDRONATE TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE
Hiligsmann, M.
Reginster, J. -Y.
[J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S182 - S182
[5] Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
Hiligsmann, M.
Reginster, J. -Y.
[J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 (03) : 649 - 658
[6] Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis
Sebba, AI
Bonnick, SL
Kagan, R
Thompson, DE
Skalky, CS
Chen, EL
de Papp, AE
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) : 2031 - 2041
[7] Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study
Rosen, CJ
Hochberg, MC
Bonnick, SL
McClung, M
Miller, P
Broy, S
Kagan, R
Chen, E
Petruschke, RA
Thompson, DE
de Papp, AE
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (01) : 141 - 151
[8] Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis
Ilter, E
Karalok, H
Tufekci, EC
Batur, O
[J]. CLIMACTERIC, 2006, 9 (02) : 129 - 134
[9] Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis (vol 20, pg 2031, 2004)
Sebba, AI
Bonnick, SL
Kagan, R
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (02) : 325 - 325
[10] The effectiveness of alendronate (70 mg weekly) in women with postmenopausal osteoporosis
Martchenkova, L. A.
Dreval, A. V.
Kryukova, I. V.
Tishenina, R. S.
Milov, N. M.
[J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S44 - S44

← 1 2 3 4 5 →